PDCD1 and head and neck squamous cell carcinoma: Overall survival (OS) was found to be significantly longer (hazard ratio 0.7), and the 1-year OS rate (36.0%) was 19% higher in patients with R/M-HNSCC who had received the anti-PD-1 antibody nivolumab than in those who had received standard therapy [3].